JPH07173062A - Pharmaceutical containing p-guanidinobenzoic acid phenyl ester derivative - Google Patents

Abstract

PURPOSE:To obtain an elastase inhibitor containing p-guanidinobenzoic acid phenyl ester derivative as an active component. CONSTITUTION:This pharmaceutical agent contains a compound of formula I (R<2> is H, an alkyl, an alkoxy, an alkoxymethyl, COOR<3>, a halogen, group of formula II, benzyloxy, guanidino, pyridyloxymethyl, etc.; R<3> is H or a 1-4C alkyl ; R<5> and R<6> each is H, a 1-4C alkyl, phenyl, pyridyl or together with N forms pyrrolidinyl, morpholino, etc.) as an active component. The agent is useful for the treatment and prevention of diseases caused by the decomposition of elastin, decomposition of collagen fiber and/or decomposition of proteoglycan by elastase of mammals, especially human, e.g. chronic pulmonary emphysema, atherosclerosis and rheumatoid arthritis. The administration rate of the agent for adult is 50-500mg per dose and 1 to several doses per day by oral administration or 10-200mg per dose by parenteral administration, preferably intravenous injection.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a drug containing a p-guanidinobenzoic acid derivative. More specifically, the general formula (IB)

[Chemical 3] (In the formula, all symbols have the same meanings as described below.) The present invention relates to an elastase inhibitor containing a p-guanidinobenzoic acid phenyl ester derivative as an active ingredient.

[0002]

BACKGROUND OF THE INVENTION The lysosome hydrolase group released from neutrophils plays an important role in the biological defense reaction against tissue damage caused by microorganisms or inflammation. Of the lysosomal enzyme group, elastase and cathepsin G, which belong to neutral serine proteinases localized in azure granules, mainly play a role of connective tissue degradation. In particular, elastase decomposes elastic connective tissue by cleaving the cross-linking structure of elastin, which functions directly to maintain the elasticity of lung tissue and the like, and the hydrophobic site of proteins [J. Cell. Biol., 40 , 366 (196
9)]. Furthermore, elastase selectively decomposes not only elastin but also the cross-linked region of collagen fibers [J. Bio
chem., 84 , 559 (1978)], and also acts on tissue structural proteins such as proteoglycan [J. Clin. Invest., 57 , 61].
5 (1976)] and plays a central role in connective tissue metabolism.

[0003] In vivo, elastase common inhibitors to serine enzyme, alpha ₁ - when there is a disturbance in the balance of the inhibitor system, - by proteinase inhibitor (α ₁ -PI) but is deactivated, an enzyme Tissue-destructive symptoms appear [Schweiz, Med. Wshr., 114 , 895 (198
Four)].

The turnover of elastin in normal tissues is very slow [Endocrinology, 120 , 92 (1978)], but emphysema [Am. Rev. Respir. Dis., 110 , 254 (1974)] and atherosclerosis. [Lab. Invest., 22 , 228 (1
970)] or rheumatoid arthritis [in Neutral Proteas
es of Human Polymorphonuclear Leukocytes, Urbanand
Under various pathological conditions such as Schwarzenberg, Baltimore-Munich (1978), p. 390], abnormal enhancement of elastin degradation was observed, and the relationship between elastase and disease has been noted [infection, inflammation, immunity, 13 ,, 13 (1983)].

[0005]

2. Description of the Related Art Under the above background, research and development of elastase inhibitors have been extensively conducted recently, and various elastase inhibitors have been proposed and applied for patents. Until now, no elastase inhibitor consisting of a guanidinobenzoic acid derivative has been known. On the other hand, various esters of p-guanidinobenzoic acid have been conventionally known. For example,

(1) Japanese Patent Publication No. 54-40534 discloses that

[Chemical 4] A compound represented by

(2) Japanese Patent Application Laid-Open No. 50-4038 discloses a general formula

[Chemical 5] (In the formula, R ^a represents an aromatic group, and the aromatic group is a lower alkyl group, a lower alkoxycarbonyl group, a carboxyl group, a carboxy lower alkyl group, a carboethoxy lower alkyl group, a lower alkoxy group, an acylamido group or a carbamoyl group. May be substituted with.) (Extracting only relevant portions) is disclosed,

(3) Japanese Patent Publication No. 57-35870 discloses a general formula

[Chemical 6] (Wherein Z ^a represents a group selected from the group consisting of ^a carbon-carbon covalent bond, a methylene group, an ethylene group and a vinylene group.) Is disclosed.

(4) Japanese Patent Application Laid-Open No. 55-55154 discloses a general formula

[Chemical 7] (Wherein Z ^b represents a methylene group, an ethylene group or a vinylene group, and R ^b represents a lower alkyl group).

(5) West German Laid-Open Patent No. 3005580 describes the general formula

[Chemical 8] (Wherein, Z ^c represents a group represented by sulfonyl groups or Z ^d -CO, Z ^d is a single bond, represents methylene, ethylene or vinylene, R ^c and / or R ^d represents hydrogen or alkyl.) A compound represented by

(6) West German Laid-Open Patent No. 1905813 describes the general formula

[Chemical 9] (Wherein R ^e and / or R ^f represents hydrogen, alkyl, aryl, nitro, amino, alkylamino, dialkylamino, alkoxy, carboxy, carboalkoxy or halogen, and l represents zero or 1). Disclosed compounds are disclosed.

(7) USP 4,423,069 describes:
General formula

[Chemical 10] [Wherein R ^g is halogen, trihalomethyl, nitrile group, formyl group, OR ⁱ , COR ⁱ , COOR ⁱ , CON
H ₂ or CONR ^j R ^k (in the formula, R ⁱ , R ^j or R ^k represents an alkyl group having 1 to 8 carbon atoms), and R ^h represents hydrogen or a group represented by the symbol R ^g. . ] A method for inhibiting conception, which comprises administering a compound represented by

(8) Japanese Patent Application Laid-Open No. 61-43151 discloses a general formula

[Chemical 11] (In the formula, R ¹ represents hydrogen, a nitrile group or an ether group, R ^m represents a hydrogen, an ether group, an ester group or a carbamoyl group, and R ¹ and R ^m do not simultaneously represent hydrogen.) Acrosin inhibitors containing the indicated compounds or salts thereof are disclosed.

However, in the above-mentioned specifications (1) to (6), since all of these compounds have the action of inhibiting trypsin and plasmin, they are hemorrhagic as a treatment for acute pancreatitis and as an antiplasmin agent. It has only been described that it is useful for diseases, and similarly, all the compounds in the above specifications (7) and (8) have an action of suppressing acrosin, which is an important enzyme at the time of fertilization. Therefore, it is only described as being useful as a fertility inhibiting method or a fertilization inhibitor.

The elastase inhibitory action of these compounds has not been mentioned at all, and no report has been made to confirm the presence or absence of the action until now.

Elastase belongs to the same serine proteinases as trypsin and plasmin (hereinafter, trypsin and plasmin are referred to as "other serine proteinases" to distinguish them from elastase), but they are enzymatic protein properties. It is very different in terms of specificity and substrate specificity. Therefore, it is preferable to consider elastase to be a group of enzymes that are essentially completely different from other serine proteinases, and it is also quite different when developing inhibitors for them. Should be considered from a different perspective. That is, elastase, especially human neutrophil elastase, has a molecular weight of about 30,000 [B
iochem. J., 155 , 255 (1976)] has an isoelectric point of pH 8.77.
To 9.15 [Anal. Biochem., 90 , 481 (1978)] basic glycoprotein ["Protein Degradation in Health a
nd Disease ", D. Evered and J. Whelan, p. 51,
Excerpta Medica, Amsterdam (1980)], and has different enzymatic protein properties from other serine proteinases. Further, in terms of substrate specificity, elastase is an endopeptidase that cleaves mainly at the C-terminal side of alanine residues, and this point also differs from other serine proteinases. Thus, the two are fundamentally different,
It is quite impossible to infer elastase inhibitors from other serine proteinase inhibitors.

[0017]

OBJECT OF THE INVENTION Based on these findings, the present inventors have conducted extensive studies to find an elastase inhibitor having a chemical structure completely different from that of conventional elastase inhibitors, and as a result, surprisingly, other The present invention has been completed by finding that a certain p-guanidinobenzoic acid phenyl ester derivative known as a serine proteinase inhibitor has an elastase inhibitory action. The fact that other serine proteinase inhibitors also have an elastase inhibitory effect was first confirmed by this experiment, and it was completely unexpected until then.

[0018]

The present invention has the general formula (IB)

[Chemical 12]

(Wherein R ² is (i) a hydrogen atom, (ii) an alkyl group having 1 to 4 carbon atoms, (iii) an alkoxy group having 1 to 4 carbon atoms, and (iv) an alkoxy group having 2 to 5 carbon atoms. Methyl group, (v)
Formula COOR ³ (In the formula, R ³ is a hydrogen atom or a carbon number of 1 to 4)
Represents an alkyl group. ), A group represented by the formula (vi) CH ₂
A group represented by COOR ³ (wherein R ³ has the same meaning as described above), (vii) formula CH═CH—COOR ³ (wherein
R ³ has the same meaning as described above. ) Group,

(Viii) halogen atom, (ix) trifluoromethyl group, (x) formula COR ⁴ (wherein R ⁴ is a carbon number of 1 to 4)
Represents an alkyl group, a phenyl group, a guanidinophenyl group, a cyclopentylmethyl group or a cyclohexylmethyl group. ), A group represented by the formula (xi) OCOR ⁴ (wherein R
⁴ has the same meaning as above. ) Group, (xii)
A group represented by the formula CH ₂ OCOR ⁴ (wherein R ⁴ has the same meaning as described above); and (xiii) a formula SO ₂ R ⁴ (in the formula, R ⁴ has the same meaning as described above). Radical, (xiv) formula O
A group represented by SO ₂ R ⁴ (wherein R ⁴ has the same meaning as described above),

(Xv) Formula CONR ⁵ R ⁶ (wherein R ⁵ and R ^5
6 independently represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, a benzyl group, a pyridyl group, or R ⁵ , R ⁶ and the nitrogen atom to which they are bonded are combined. Represents a pyrrolidinyl group, a piperidino group, or a morpholino group. ), A group represented by the formula (xvi) OCONR ⁵ R ⁶ (wherein R ⁵ and R ⁶ have the same meanings as described above), and a group represented by the formula (xvii) SO ₂ NR ⁵ R
⁶ (In the formula, R ⁵ and R ⁶ have the same meanings as described above.)
A group represented by the formula (xviii)

[Chemical 13] (Wherein R ⁵ and R ⁶ have the same meanings as described above),

[0022] (xix) formula NHSO ₂ R ⁷ (wherein, R ⁷ represents. Alkyl group or a phenyl group having 1 to 4 carbon atoms) groups represented by, (xx) a nitro group, (xxi) a hydroxyl group, ( xxii) hydroxymethyl group, (xxiii) guanidino group, (xxiv) benzyloxy group, (xxv) guanidinophenylthiomethyl group, (xxvi) morpholinosulfonylphenoxymethyl group, (xxvii) pyridyloxymethyl group or (xxviii)
When (1,1-dioxothiazol-3-yl) carbonyl group is represented, n is an integer of 1 to 5, and n is an integer of 2 or more, each R ² may be the same as each other. Or it may be different. ) The p-guanidinobenzoic acid phenyl ester derivative represented by the formula (4) and an elastase inhibitor containing an acid addition salt thereof as an active ingredient.

In this specification, including the claims,
When simply referred to as "alkyl group", it is intended to mean a straight or branched chain alkyl group. General formula (I
Alkyl group represented by R ² in B), and the alkyl moiety in the alkoxy group represented by R ^2, and as the R ^3, R ^4, an alkyl group represented by R ^5, R ⁶ and R ^7, methyl, ethyl , Propyl, butyl groups and isomers thereof, any group being preferred. In the general formula (IB), examples of the halogen atom represented by R ² include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and any group is preferable. In formula (IB), the group represented by R ² is preferably any group represented by (i) to (xxviii).

The acid addition salt of the compound represented by formula (IB) is preferably non-toxic and water-soluble. Suitable acid addition salts include, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate or acetate, lactate, tartrate, benzoate. Acid salt, citrate, methane sulfonate, ethane sulfonate,
Organic acid salts such as benzene sulfonate, toluene sulfonate, isethionate, glucuronate and gluconate are mentioned.

All the compounds represented by formula (IB) can be produced by a known method. For example, the general formula (II)

[Chemical 14] (Wherein, X represents a halogen atom) and an acid addition salt of the compound represented by the general formula (III)

[Chemical 15] (In the formula, R ² and n have the same meanings as described above.) The compound is produced by reacting.

Since the above reaction is a condensation reaction which produces hydrogen halide as a by-product, it is advantageous to add a dehydrohalogenating agent in order to accelerate the reaction. As such a dehydrohalogenating agent, a tertiary organic amine, and if desired, an inorganic base such as a metal bicarbonate can be used. As the tertiary organic amine, an aliphatic or aromatic or heterocyclic amine, for example, triethylamine, tributylamine,
Dimethylaniline, pyridine, etc. are used. Of these, pyridine is particularly preferable because it also acts as a solvent for the reaction components. Examples of the inorganic base include sodium bicarbonate,
Sodium carbonate, caustic soda, etc. are used.

As the solvent, for example, benzene, toluene, tetrahydrofuran, pyridine and the like can be used. As described above, pyridine is particularly preferable because it also acts as a dehydrohalogenating agent.

Since the reaction proceeds relatively quickly, it may be carried out at room temperature, if desired with a slight cooling, generally 0 ° C.
It is recommended to carry out at room temperature. The reaction time varies depending on the reaction temperature used, but generally 30 minutes to 4 hours, preferably 30 minutes to 2.5 hours is sufficient.

In carrying out the reaction, the starting compound (III) is dissolved in a solvent, preferably pyridine, and the starting compound (II) is added to this solution. The starting compound (II) does not dissolve when pyridine is used as a solvent, and thus the reaction becomes a heterogeneous system, but since the target product dissolves in pyridine as the reaction progresses, it eventually forms a homogeneous solution. . When a solvent other than pyridine is used, a homogeneous system is not always obtained, but the reaction can be carried out even in a heterogeneous system.

The desired product is formed in the form of a salt with hydrogen halide. In decomposing this target product, depending on the solvent used, it may be concentrated, or sodium bicarbonate may be added without concentration to convert the product into a carbonate, which precipitates as crystals. In particular, when pyridine is used as a solvent, crystals are precipitated by directly converting to carbonate without evaporative concentration. Of course, the desired product can be obtained by evaporating the solvent to dryness, but it is preferable to precipitate the crystals as described above because a purified product having a high purity can be obtained.

Compound (IB) thus obtained
Can be further converted, if desired, into the appropriate acid addition salt described above by a known method. Further, when it does not precipitate as crystals in the process of converting to the above salt, it can be purified by column chromatography using silica gel or the like.

The starting compound (II) used in the above reaction is p
It can be prepared in the usual way by reacting guanidinobenzoic acid with thionyl chloride. In this case, the raw material compound (II) produced is a hydrogen halide salt, particularly a hydrochloride salt. The raw material compound (II) is obtained as a salt of hydrogen halide produced as a by-product when the acid halide (II) is produced from p-guanidinobenzoic acid, and it is advantageous to use this salt as it is. The compound represented by the general formula (III) is a known compound or can be easily produced by a known method.

Further, among the compounds represented by the general formula (IB), compounds in which at least one of R ² represents a carboxyl group, that is, the general formula (IB-a)

[Chemical 16] (In the formula, R ^2a represents a group represented by R ² excluding a carboxyl group, p represents an integer in the range of 1 to 5, and q represents 0 or an integer in the range of 1 to 4. Represents.)
The compound represented by the general formula (IV)

[Chemical 17] (In the formula, the symbol φ represents a phenyl group and the other symbols have the same meanings as described above.) The compound can be obtained by subjecting the compound to a debenzylation reaction. Such debenzylation reaction is carried out in an atmosphere of an inert gas (eg, argon, nitrogen etc.) using, for example, an anhydrous hydrogen bromide-acetic acid solution. The temperature is generally 0 to 50 ° C., preferably room temperature.

The compound (IV) is a compound represented by the general formula (V) with an acid addition salt of the compound represented by the general formula (II).

[Chemical 18] (In the formula, all symbols have the same meanings as described above.) The compound can be obtained by subjecting the compound to an esterification reaction. This reaction is carried out as described above.

The compound (V) has the general formula (VI)

[Chemical 19] (In the formula, all symbols have the same meanings as described above.) The compound can be obtained by subjecting it to a benzylation reaction. The benzylation reaction is performed by a known method. The compound represented by the general formula (VI) is a known compound or can be easily produced by a known method.

Of the compounds represented by the general formula (IB), R
^A compound in which at least one of ² represents a hydroxymethyl group, that is, a compound represented by the general formula (IB-b)

[Chemical 20] (In the formula, R ^2b represents a group represented by R ² excluding a hydroxymethyl group, r represents an integer in the range of 1 to 5, and s represents 0 or in the range of 1 to 4. Represents an integer, r + s represents an integer within a range of 1 to 5, and the other symbols have the same meanings as described above.) Is a compound represented by the general formula (VII).

[Chemical 21] (In the formula, THP represents a 2-tetrahydropyranyl group, and other symbols have the same meanings as described above.) The compound represented by the formula (II) is subjected to a deTHP-forming reaction. Such de-THP reaction is carried out, for example, in an aqueous solution of an organic acid such as acetic acid, propionic acid, oxalic acid or p-toluenesulfonic acid (preferably acetic acid) or an aqueous solution of an inorganic acid such as hydrochloric acid or sulfuric acid, preferably water It may be carried out at room temperature to 75 ° C. (preferably 37 ° C. or higher) in the presence of a miscible organic solvent such as methanol or ethers such as 1,2-dimethoxyethane, dioxane or tetrahydrofuran.

The compound (VII) is obtained by adding an acid non-addition salt of the compound represented by the general formula (II) to the general formula (VIII).

[Chemical formula 22] (In the formula, all symbols have the same meanings as described above.) The compound can be obtained by subjecting the compound to an esterification reaction. Such a reaction is carried out as described above.

The compound represented by the formula (VIII) has the general formula (IX)

[Chemical formula 23] (In the formula, all symbols have the same meanings as described above.) The compound can be obtained by subjecting to a debenzylation reaction. Such debenzylation reaction is generally carried out at a temperature of 0 to 40 ° C. (preferably at room temperature) using hydrogen-gas atmosphere, using palladium-carbon as a catalyst and ethyl acetate, ethanol, benzene and the like. Be done. The compound represented by the formula (IX) is a known compound, or can be obtained by a known method.

Further, among the compounds represented by the general formula (IB), the general formula (IB-c)

[Chemical formula 24]

(In the formula, R ^2c is (i) a hydrogen atom, (ii) an alkyl group having 1 to 4 carbon atoms, (iii) an alkoxy group having 1 to 4 carbon atoms, and (iv) an alkoxy group having 2 to 5 carbon atoms. Methyl group, (v)
Formula COOR ³ (In the formula, R ³ has the same meaning as described above.)
A group represented by (vi) a group represented by the formula CH ₂ COOR ³ (wherein R ³ has the same meaning as described above),

(Vii) a halogen atom, (viii) a trifluoromethyl group, (ix) a group represented by the formula COR ⁴ (wherein R ⁴ has the same meaning as described above), and (x) a formula OCOR ⁴ ( In the formula, R ⁴ represents the same meaning as described above),
(xi) a group represented by the formula CH ₂ OCOR ⁴ (wherein R ⁴ has the same meaning as described above), and (xii) a formula SO ₂ R ⁴ (in the formula, R
⁴ has the same meaning as above. ) Group, (xiii)
A group represented by the formula OSO ₂ R ⁴ (wherein R ⁴ has the same meaning as described above),

(Xiv) A group represented by the formula CONR ⁵ R ⁶ (wherein R ⁵ and R ⁶ have the same meanings as described above), (xv)
A group represented by the formula OCONR ⁵ R ⁶ (wherein R ⁵ and R ⁶ have the same meanings as described above), and (xvi) the formula SO ₂ R ⁵ R
⁶ (In the formula, R ⁵ and R ⁶ have the same meanings as described above.)
Group represented by, (xvii) formula

[Chemical 25] (Wherein R ⁵ and R ⁶ have the same meanings as described above),

(Xviii) A group represented by the formula NHSO ₂ R ⁷ (wherein R ⁷ has the same meaning as described above), (xix) hydroxyl group, (xx) hydroxymethyl group, (xxi) guanidino group,
(xxii) benzyloxy group, (xxiii) guanidinophenylthiomethyl group, (xxiv) morpholinosulfonylphenoxymethyl group, (xxv) pyridyloxymethyl group or (x
xvi) represents a (1,1-dioxothiazol-3-yl) carbonyl group, n ′ represents an integer of 1 to 5, and n ′
When R represents an integer of 2 or more, R ^{2c s} may be the same as or different from each other. )
The compound represented by

General formula (X)

[Chemical formula 26] (In the formula, R ^2c and n ′ have the same meanings as described above.)
And a compound of formula (XI)

Embedded image It can also be produced by reacting a cyanamide represented by NH ₂ —CN (XI).

In the above reaction, the starting compound (X) is added to water or an inert organic solvent such as methanol, ethanol or tetrahydrofuran, or a mixed solvent of water and alcohol to prepare an equimolar amount or excess amount of the compound (X). It is carried out by adding an excess of the compound of formula (XI) in the presence of a mineral acid such as hydrochloric acid or sulfuric acid, and reacting at room temperature to the reflux temperature of the reaction mixture for 15 minutes to 2 hours. The produced target compound is isolated and purified in the same manner as in the above method, and if desired, converted to an acid addition salt. The starting compound (X) used in the above reaction is obtained by dissolving the corresponding p-nitrobenzoic acid phenyl ester compound in a lower alkanol such as ethanol, and then adding palladium carbon, palladium black, platinum dioxide, nickel under normal temperature or normal pressure or warm pressure. It can be easily produced by catalytic reduction in the presence of a hydrogenation catalyst such as. The other raw material, cyanamide (XI), is a known compound.

[0046]

INDUSTRIAL APPLICABILITY Since the p-guanidinobenzoic acid phenyl ester derivative represented by the general formula (IB) and the acid addition salt thereof according to the present invention have an elastase inhibitory action, elastin degradation by elastase in mammals, particularly humans. , And is useful for the treatment and / or prevention of diseases caused by abnormal increase of collagen fiber degradation and / or proteoglycan degradation. Such diseases include emphysema, atherosclerosis and rheumatoid arthritis.

Inhibitory Action on Elastase The inhibitory action of the compounds of the present invention on the elastase was confirmed by the screening system described below.

(I) Experimental method Using human neutrophil elastase, the method of Bieth et al. [Bio
Chem. Med., 75 , 350 (1974)]. That is, a synthetic substrate [succinyl-alanyl-] having relatively high specificity for neutrophil elastase
Prolyl-alanyl-p-nitroanilide (Suc-Ala-Pr
o-Ala-pNA, manufactured by Peptide Research Laboratories)]. 1 mM Suc-Ala-Pro-Ala-pNA (dissolved in 100 mM with N-methylpyridone and added 1/100 of the amount to the reaction mixture), 0.1 M Tris-HCl buffer (pH 8.
0), 0.2 M aqueous sodium chloride solution, 1 ml of a reaction mixture containing various concentrations of the sample solution and the enzyme solution was incubated at 37 ° C. for 30 minutes. 100 μl of 50% acetic acid in the reaction solution
Was added to stop the reaction, the released p-nitroanilide was measured by the absorbance at 405 nm, and the inhibition rate was calculated by the following formula.

Inhibition rate (%) = (1- (specimen value-blank value) / (control value-blank value) * 100

(Ii) Results The results are shown in Table 1.

[0051]

[Table 1]

[0052]

[Table 2]

[0053]

[Table 3]

[0054]

[Table 4]

[0055]

[Table 5]

[0056]

[Table 6]

[0057]

[Table 7]

[0058]

[Table 8]

[0059]

[Table 9]

[0060]

[Table 10]

1) This compound is the compound described in Example 4 of JP-A-50-4038. 2) The% inhibition is shown when the drug concentration is 50 μg / ml.

From the experimental results, it was confirmed that the compound according to the present invention has an elastase inhibitory action. Furthermore, the toxicity of the compound according to the present invention was sufficiently low, and it was confirmed that it can be used as a drug sufficiently safely. For example, in an acute toxicity test by intravenous administration using mice, (R ² ) _n in the general formula (IB) is 2,5-dichloro, hydrogen atom, 3-chloro-5-hydroxy, 3-chloro-5- Ethanesulfonyloxy and 3-chloro-
The LD ₅₀ values of the compound representing 4- (N, N-diethylsulfamoyl) were both in the range of _{50 to} 150 mg / Kg. Therefore, it was confirmed that the compound of the present invention is useful for the treatment and / or prevention of diseases caused by abnormally enhanced degradation of elastin and other proteins by elastase in mammals, especially humans.

To use the compound represented by the general formula (IB) and its acid addition salt for the above purpose, it is usually administered systemically or locally, orally or parenterally. The dose varies depending on age, weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually 50 mg per adult per dose
~ 500 mg orally administered once to several times a day, or 10 mg to 20 times per adult per adult
It is administered parenterally (preferably intravenously) once to several times a day in the range of 0 mg. Of course, as described above, since the dose varies depending on various conditions, a dose smaller than the above dose range may be sufficient in some cases, or a dose exceeding the range may be necessary in some cases.

Solid compositions for oral administration according to the present invention include tablets, powders, granules and the like. In such solid compositions, the one or more active substances are at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, aluminometasilicate. Mixed with magnesium acid. The composition comprises, according to a conventional method, additives other than an inert diluent, for example, a lubricant such as magnesium stearate, a disintegrant such as calcium fibrin glycolate, a stabilizer such as lactose, glutamic acid or asparagine. It may contain a solubilizing agent such as an acid. If necessary, the tablets or pills may be coated with a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, or may be coated with two or more layers. Also included are capsules of absorbable material such as gelatin. Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and generally used inert diluents such as purified water. , Including ethanol. This composition may contain, in addition to an inert diluent, auxiliary agents such as a wetting agent and a suspending agent, a sweetening agent, a flavoring agent, an aromatic agent and a preservative. Other compositions for oral administration include spray formulations which contain one or more active substances and are formulated in a manner known per se. The composition may contain, in addition to an inert diluent, a stabilizer such as sodium bisulfite and a buffer such as sodium chloride, sodium citrate or citric acid to provide isotonicity. A method for producing a spray agent is described, for example, in US Pat.
2868691 and 3095355.

The injections for parenteral administration according to the present invention include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of the aqueous solution and suspension include distilled water for injection and physiological saline. Examples of non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 and the like. Such compositions may further contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (eg lactose), solubilizers (eg glutamic acid, aspartic acid). . These are sterilized by, for example, filtration through a bacteria-retaining filter, blending of a bactericide, or irradiation. These can also be used by preparing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use. Other compositions for parenteral administration include external preparations containing one or more active substances and formulated by a method known per se, coating agents such as ointments, suppositories for rectal administration. And pessaries for vaginal administration.

[0066]

The present invention will be described in detail below with reference to reference examples and examples, but the present invention is not limited to these examples. In addition, "IR" in the examples represents "infrared absorption spectrum", and unless otherwise specified, it is measured by the KBr method. Moreover, "mesylate" in the table means "methanesulfonate".

Reference Example 1 p-guanidinobenzoic acid 3,5-dichlorophenyl ester methanesulfonate

[Chemical 28]

P-guanidinobenzoyl chloride hydrochloride (West German Patent No. 3005580 and US Pat. No. 42834).
It was prepared by the method described in each Example 1 of the specification No. 18. ) 700 mg, 3,5-dichlorophenol 4
A mixture of 90 mg and 10 ml of pyridine was added under ice cooling to 3
Stir for 0 minutes. Diethyl ether was added to the reaction mixture and decantation was performed, and a saturated aqueous solution of sodium hydrogencarbonate was added to the obtained supernatant to obtain the desired carbonate. The obtained crystals were washed successively with water and acetone and dried under vacuum. Crystals were suspended in ethanol and methanesulfonic acid was added to
124 mg was added, and the precipitated crystals were vacuum dried to obtain 506 mg of the title compound (white crystals) having the following physical data. Melting point: 232-234 ° C .; IR value: ν 3340, 3150, 1730, 1680, 1620, 1600, 15
70, 1550, 1410, 1260, 1200, 1170, 1090, 1060, 1040
cm ^-1 .

In the same manner as in Reference Example 1, p-guanidinobenzoyl chloride hydrochloride and the corresponding phenol compound were used to obtain the compounds shown in Table 2.

[Chemical 29]

[0070]

[Table 11]

[0071]

[Table 12]

[0072]

[Table 13]

[0073]

[Table 14]

[0074]

[Table 15]

[0075]

[Table 16]

[0076]

[Table 17]

[0077]

[Table 18]

[0078]

[Table 19]

[0079]

[Table 20]

[0080]

[Table 21]

[0081]

[Table 22]

[0082]

[Table 23]

[0083]

[Table 24]

[0084]

[Table 25]

[0085]

[Table 26]

[0086]

[Table 27]

[0087]

[Table 28]

[0088]

[Table 29]

[0089]

[Table 30]

[0090]

[Table 31]

[0091]

[Table 32]

[0092]

[Table 33]

[0093]

[Table 34]

[0094]

[Table 35]

Reference Example 124 p-guanidinobenzoic acid 3-carboxy-2-chlorophenyl ester-hydrobromide

[Chemical 30]

3-carboxy-2-chlorophenol 7
After adding 4 ml of 1N sodium hydroxide to 00 mg,
Concentration under reduced pressure gave the corresponding sodium salt. The sodium salt was dissolved in 20 ml of hexamethylphosphoramide, 0.58 ml of benzyl bromide was added, and the mixture was stirred overnight. The reaction mixture was diluted with diethyl ether, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Residue and p-guanidinobenzoyl chloride hydrochloride (JP-A-55-115865 and U.S. Pat. No. 4,283,418).
It was prepared by the method described in each Example 1 of the specification. ) 1 g was stirred in pyridine in an ice-water bath for 15 minutes. Diethyl ether was added to the reaction mixture, the mixture was decanted, saturated aqueous sodium hydrogencarbonate solution was added to the insoluble residue, and the crystals were filtered, washed with water and acetone in that order, and dried under vacuum. 200 mg of the obtained crystal was added with about 5 ml of 30% hydrogen bromide-acetic acid in an argon atmosphere, and the mixture was stirred at room temperature for 3 hours. Diethyl ether was added to the reaction mixture, and the precipitated crystals were washed with diethyl ether and vacuum dried to obtain 192 mg of the title compound (yellow powder) having the following physical data. Melting point: 220-227 ° C.

Then, the compounds of Reference Example 125 and Reference Example 126 having the physical properties shown in Table 3 were obtained in the same manner as in Reference Example 124.

[Table 36]

Reference Example 127 p-guanidinobenzoic acid 3-chloro-5-hydroxymethylphenyl ester acetic acid salt

[Chemical 31]

3-Chloro-5-hydroxybenzoic acid 1.97
0 g was dissolved in 30 ml of dimethylformamide, 601 mg of sodium hydride was added, and the mixture was stirred at room temperature for 10 minutes. To the reaction solution was added 4.288 g of benzyl bromide, and the mixture was stirred at room temperature for 2 hours. After adding 30 ml of ethyl acetate to the reaction mixture, the mixture was washed several times with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (eluting solvent, hexane: ethyl acetate = 1.
3-chloro- having the following physical properties by purification with 0: 1)
3.61 g of 5-benzyloxybenzoic acid benzyl ester was obtained. TLC (hexane: ethyl acetate = 10: 1): Rf 0.
26.

3.61 g of benzyl compound was added to tetrahydrofuran 5
It was dissolved in 0 ml, lithium aluminum hydride (579 mg) was added, and the mixture was reacted at room temperature for 2 hours. Ethyl acetate was added to the reaction mixture to decompose excess reagents and
It was poured into a normal sodium hydroxide aqueous solution. After the reaction mixture was extracted with diethyl ether, the extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluting solvent, dichloromethane) to give the following physical properties 3 -Chloro-5
1.502 g of benzyloxybenzyl alcohol was obtained. TLC (chloroform: methanol = 10: 1): Rf
0.69.

1.502 g of alcohol was added to dichloromethane 2
It was dissolved in 0 ml, 655 mg of dihydropyran and a catalytic amount of p-toluenesulfonic acid were added, and the mixture was reacted at room temperature for 1 hour. Add a small amount of pyridine to the reaction mixture and wash with water,
Further concentrated. The obtained residue was subjected to silica gel column chromatography (eluting solvent, hexane: ethyl acetate =
3-chloro-5-benzyloxybenzyl alcohol-O- (2- having the following physical properties.
1.83 g of tetrahydropyranyl) ether was obtained. TLC (hexane: ethyl acetate = 10: 1): Rf 0.
20.

The obtained benzyl derivative (996 mg) was dissolved in ethyl acetate (7 ml), and debenzylated at room temperature, atmospheric pressure and hydrogen atmosphere using 10% palladium carbon as a catalyst. Three
After a lapse of time, the reaction was completed, and the obtained crude product was purified by silica gel column chromatography (eluting solvent, hexane: ethyl acetate = 5: 1) to give 3-chloro-5- (2- Tetrahydropyranyloxymethyl)
274 mg of phenol was obtained. TLC (hexane: ethyl acetate = 5: 3): Rf 0.2
Four.

274 mg of phenol compound was added to 3 ml of pyridine.
And 396 mg of p-guanidinobenzoyl chloride hydrochloride was added, and the mixture was reacted at room temperature for 2 hours. 20 ml of diethyl ether was added to the reaction mixture, and the precipitate was collected by filtration. The precipitate was washed with diethyl ether. An aqueous sodium hydrogencarbonate solution was added to the insoluble residue, and the produced carbonate was filtered off. The crude carbonate was dissolved in 60% acetic acid (3 ml) and reacted at 37 ° C. for 2 hours. After distilling off acetic acid under reduced pressure, the residue was subjected to silica gel column chromatography (elution solvent, chloroform: methanol: acetic acid = 10: 2:
Purified in 1), 100m of the title compound having the following physical data
g was obtained. TLC (chloroform: methanol: acetic acid = 10: 2:
1): Rf 0.26; NMR (CD ₃ OD): δ 8.2 (2H, d, J = 8Hz), 7.42 (2H, d, J = 8H)
z), 7.30 (1H, bs), 7.16 (2H, bs), 4.64 (2H, s).

Reference Example 128 p-guanidinobenzoic acid 3-chloro-5- (4-morpholinosulfonyl) phenoxymethylphenyl ester
Acetate

[Chemical 32]

3-Chloro-5-hydroxybenzoic acid 40
4 mg was dissolved in 10 ml of dichloromethane, and further 256 mg of dihydropyran was added. A catalytic amount of p-toluenesulfonate was added, and the mixture was reacted at room temperature for 1 hour. A small amount of pyridine was added to the reaction mixture, which was further washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain the corresponding product (2
-Tetrahydropyranyl) ether was obtained. The obtained crude product was used for the next reaction without purification. That is, the crude product was dissolved in 10 ml of tetrahydrofuran and cooled in an ice-water bath, and 133 mg of lithium aluminum hydride was added to this mixed solution and stirred. After raising the reaction temperature to room temperature and reacting for 1 hour, ethyl acetate was added to the reaction mixture to decompose excess reagent. The reaction mixture was poured into 20 ml of 1N sodium hydroxide, the mixture was extracted with ethyl acetate and concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (elution solvent, hexane: ethyl acetate = 5: 2). With the following physical properties,
541 mg of chloro-5- (tetrahydropyranyloxy) benzyl alcohol was obtained. TLC (hexane: ethyl acetate = 5: 3): Rf 0.
Five.

The obtained alcohol derivative (484 mg) was dissolved in dichloromethane (10 ml). To this mixed solution, 242 mg of triethylamine was added, cooled in an ice-water bath, and 273 mg of methanesulfonyl chloride was added dropwise. After the reaction temperature was raised to room temperature, it was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain the corresponding mesylate. The obtained crude product was used for the next reaction without purification. p-morpholino sulfonylphenol 460 mg
Was dissolved in a mixed solution of 7 ml of tetrahydrofuran and 1 ml of hexamethylphosphoramide. Sodium hydride (57.6 mg) was added to this mixture, and the mixture was stirred for 10 minutes.
Then, the mesylate obtained above was added to this reaction solution and reacted at room temperature for 1 hour. Water was added to the reaction mixture, which was extracted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. 5 ml of the obtained crude product is methanol
It is dissolved in a mixed solvent of 5 ml of tetrahydrofuran and tetrahydrofuran, 50 mg of p-toluenesulfonic acid is further added, the mixture is reacted at room temperature for 2 hours, the solvent is distilled off, and the residue is purified by silica gel column chromatography (hexane: ethyl acetate = 5: 3). And 3-chloro-5- (4-morpholinosulfonyl) phenoxymethylphenol 22 having the following physical properties
8 mg was obtained. TLC (hexane: ethyl acetate = 5: 3): Rf 0.1
8.

228 mg of phenol, 207 mg of p-guanidinobenzoyl chloride hydrochloride and pyridine 3
Esterification was carried out in the same manner as in Reference Example 1 using ml. The product is subjected to silica gel column chromatography (elution solvent,
Purification with ethyl acetate: acetic acid: water = 400: 100: 30) gave 150 mg of the title compound having the following physical data. TLC (chloroform: methanol: acetic acid = 10: 2:
1): Rf 0.7; IR: ν 3600 to 2500, 1720, 1680, 1560, 1400, 1330
cm ^-1 .

Reference Example 129 p-guanidinobenzoic acid 3-methoxy-5- (4-morpholinosulfonyl) phenoxymethylphenyl ester / acetate

[Chemical 33]

According to the same production method as described in Reference Example 128,
The title compound (white powder) having the following physical data was obtained. TLC (ethyl acetate: acetic acid: water = 400: 100: 3
0): Rf 0.72; IR: ν 3600 to 2500, 1720, 1680, 1590, 1400, 1340
cm ^-1 .

Example 1 10 g of p-guanidinobenzoic acid 3-chloro-5-hydroxyphenyl ester methanesulfonate (prepared in Reference Example 1), calcium fibrin glycolate (disintegrant) 400 mg, magnesium stearate ( lubricant)
200 mg and 9.4 g of microcrystalline cellulose were mixed by a conventional method and compressed to give 100 tablets each containing 100 mg of active ingredient.

Example 2 1 g of p-guanidinobenzoic acid 3-chloro-5-hydroxyphenyl ester methanesulfonate (prepared in Reference Example 1) was dissolved in 10 ml of ethanol, and sterilized through a bacteria-retaining filter to obtain 5 ml. 50 ampules by adding 0.5 ml per ampule
The ampoule was sealed so that it contained mg of drug.
The content of the ampoule should be a suitable volume of diluent, for example pH 8.
It is diluted to 2.5 ml with Tris-HCl buffer of 6 and used as an injection.

Example 3 10 g of p-guanidinobenzoic acid 3-chloro-5-ethanesulfonyloxyphenyl ester methanesulfonate (prepared in Reference Example 1), calcium fibrin glycolate (disintegrant) 400 mg, stearic acid 200 mg of magnesium (lubricant) and 9.4 g of microcrystalline cellulose were mixed by an ordinary method and compressed to give 100 tablets each containing 100 mg of active ingredient.

Example 4 1 g of p-guanidinobenzoic acid 3-chloro-5-ethanesulfonyloxyphenyl ester methanesulfonate (prepared in Reference Example 1) was dissolved in 10 ml of ethanol and sterilized through a bacteria-retaining filter. And 5m
The ampoule was sealed by adding 0.5 ml per 1-volume ampoule so that the drug contained 50 mg per ampoule. The content of the ampoule is diluted to 2.5 ml with an appropriate volume of a diluting solution, for example, Tris-HCl buffer having a pH of 6.8, and used as an injection.

Continuation of front page (51) Int.Cl. ⁶ Identification code Internal reference number FI technical display C12N 9/99

Claims (1)

[Claims] 1. A compound represented by the general formula (IB): (In the formula, R ² is (i) a hydrogen atom, (ii) an alkyl group having 1 to 4 carbon atoms, (iii) an alkoxy group having 1 to 4 carbon atoms, (iv)
An alkoxymethyl group having 2 to 5 carbon atoms, (v) formula COOR ³
(In the formula, R ³ represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.), (Vi) Formula CH ₂ COOR ³
(Wherein R ³ has the same meaning as described above), (vii) a group represented by the formula CH═CH—COOR ³ (wherein R ³ has the same meaning as described above), (viii) halogen atom, (ix) trifluoromethyl group, (x) formula COR ⁴
(In the formula, R ⁴ represents an alkyl group having 1 to ⁴ carbon atoms, a phenyl group, a guanidinophenyl group, a cyclopentylmethyl group or a cyclohexylmethyl group.), (Xi) Formula OCOR ⁴ (wherein R ^{4 4} represents the same meaning as described above), (xii) a group represented by the formula CH ₂ OCOR ⁴ (in the formula, R ⁴ represents the same meaning as described above),
(xiii) a group represented by the formula SO ₂ R ⁴ (wherein R ⁴ has the same meaning as described above), and (xiv) the formula OSO ₂ R ⁴ (in the formula, R ⁴
Represents the same meaning as described above. A group represented by (xv) formula CONR ⁵ R ⁶ (wherein R ⁵ and R ⁶ are each independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, a benzyl group or a pyridyl group). Or a group represented by R ⁵ , R ⁶ and the nitrogen atom to which they are attached together represent a pyrrolidinyl group, a piperidino group, or a morpholino group), (xvi) Formula OCONR ⁵
A group represented by R ⁶ (in the formula, R ⁵ and R ⁶ have the same meanings as described above), (xvii) formula SO ₂ NR ⁵ R ⁶ (in the formula,
R ⁵ and R ⁶ have the same meanings as described above. A group represented by the formula (xviii): (Wherein R ⁵ and R ⁶ have the same meanings as described above), (xix) Formula NHSO ₂ R ⁷ (In the formula, R ⁷ represents an alkyl group having 1 to 4 carbon atoms or a phenyl group. Group), (xx) nitro group, (xxi) hydroxyl group, (xxii) hydroxymethyl group, (xxiii) guanidino group, (xxiv) benzyloxy group, (xxv) guanidinophenylthiomethyl group, (xxvi ) Morpholinosulfonylphenoxymethyl group, (xxvii) pyridyloxymethyl group or (xxviii)
When (1,1-dioxothiazol-3-yl) carbonyl group is represented, n is an integer of 1 to 5, and n is an integer of 2 or more, each R ² may be the same as each other. Or it may be different. The elastase inhibitor containing the p-guanidino benzoic acid phenyl ester derivative shown by these), or its acid addition salt as an active ingredient.